|
Sex (men/women), n (%)
|
5 (71.4)/2 (28.6)
|
11 (64.7)/6 (35.3)
|
0.64
|
|
Age (years)*
|
38.6 ± 20.7
|
43.1 ± 15.2
|
0.64
|
|
Disease duration (years)*
|
7.2 ± 3.5
|
6.8 ± 4.3
|
0.68
|
|
Modified Truelove and Witts severity index*
|
7.9 ± 3.6
|
10.3 ± 3.0
|
0.23
|
|
Mayo score (endoscopy)*
|
3.0 ± 0.0
|
2.7 ± 0.5
|
0.02
|
|
Extent of disease
| | | |
|
Left-side type, n (%)
|
2 (28.6)
|
10 (58.8)
|
0.17
|
|
Extensive colitis, n (%)
|
5 (71.4)
|
7 (41.2)
|
|
Concomitant medications
| | | |
|
Corticoteroids, n (%)
|
0 (0.0)
|
7 (41.2)
|
0.04
|
|
Azathioprine/Mercaptopurine, n (%)
|
4 (57.1)
|
9 (52.9)
|
0.85
|
|
Tacrolimus, n (%)
|
3 (42.9)
|
5 (29.4)
|
0.53
|
|
Hemoglobin >9.8 g/dl at IFX initiation, n (%)
|
5 (71.4)
|
10 (58.8)
|
0.56
|
|
Serum albumin >35 g/L at IFX initiation, n (%)
|
2 (28.6)
|
10 (58.8)
|
0.18
|
|
Serum CRP <5 mg/L at 2 weeks after IFX initiation, n (%)
|
6 (85.7)
|
12 (70.6)
|
0.44
|
